Are you interested in connecting with the global HTA community and in learning more about the activities and discussions of one of the HTAi Interest Groups?
The newly-established Rare Diseases Interest Group (RDIG) is looking for a dedicated and enthusiastic individual who is willing to provide one to two days a month to support their Chair(s) and Steering Committee as a Technical Officer (TO), from now to December 2023.
Examples of responsibilities include defining agendas, setting calls and taking minutes, writing reports, supporting project work and scientific papers, drafting press releases and other similar activities.
About the RDIG
The RDIG will explore how evidence generation for HTA can be improved in rare diseases (RDs) and how HTA processes can account for the complexities that arise in the determination of value for health technologies in RD populations.
The aims of the RDIG are to:
- Develop awareness of the specific challenges associated with studying rare disease populations, not just in terms of small populations, but in understanding natural history and disease progression, paucity of knowledge about optimal endpoints given complex disease manifestations in diseases that are often chronic and implications of studying diseases that predominantly have childhood onset and are genetic, etc.
- Share good practices in generation and interpretation of evidence in RD populations for HTA purposes.
- Explore how HTA (assessment and appraisal) processes can consider wider aspects of value in RD populations within the context of fairness to society, setting new standards for HTA in RDs.
How to Apply
If you would like to apply, please complete and submit the HTAi Technical Officer Application Form along with your CV to [email protected] by Thursday, July 20, 2023.
The successful candidate will be notified by the end of July. Please note that you must be an HTAi member in good standing to apply for this position. If you have not renewed your membership for 2023, you can do so here.
Questions
Please direct all questions to [email protected].
